Merial Limited v Bayer Intellectual Property GmbH

Link copied
Case Copied 13 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Merial Limited v Bayer Intellectual Property GmbH [2015] APO 16

Patent Application:                2007341647

Title:Agents for controlling parasites on animals

Patent Applicant:                   Bayer Intellectual Property GmbH

Opponent:  Merial Limited

Delegate:  Dr S.D. Barker

Decision Date:  14 April 2015

Hearing Date:  Written submissions finalised on 26 March 2015

Catchwords:  PATENTS – whether evidence is evidence in reply – whether to rely on information pursuant to regulation 5.23 – regard had to the nature of the information and whether the information is likely, if not certain, to change the outcome of the opposition in a significant way

Representation:  Patent applicant:  Davies Collison Cave

Opponent:FB Rice

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:                2007341647

Title:Agents for controlling parasites on animals

Patent Applicant:                   Bayer Intellectual Property GmbH

Date of Decision:                   14 April 2015

DECISION

Paragraphs [50] – [52] of the declaration of Dr Clark are not evidence in reply, and do not form part of the evidence in the opposition.

The references to D18 in the declaration of Dr Witchey-Lakshmanan are not evidence in reply, and do not form part of the evidence in the opposition.

Regulation 5.23 is not invoked in relation to D18 or paragraphs [50] – [52] of the Clark declaration.

REASONS FOR DECISION

  1. This matter concerns material filed as evidence in reply and is determined under the Patents Regulations (the Regulations) as amended on 15 April 2013 by the Intellectual Property Legislation Amendment (Raising the Bar) Regulation 2013 (No 1) (the Amendment Regulation).

    Background

  2. Patent application 2007341647 in the name of Bayer Intellectual Property GmbH (Bayer) is under opposition by Merial Limited (Merial).  Evidence in reply was completed on 5 February 2015.  On 20 February 2015 Bayer wrote to the Commissioner advising that it considered that portions of the evidence filed in reply was actually evidence in support filed out of time.  A delegate of the Commissioner advised the parties on 2 March 2015 that he considered that the evidence was prima facie in reply, except those matters that related to a document designated as D18.  The delegate then stated that he was not satisfied that D18 should be relied upon under regulation 5.23.  Merial objected to this conclusion, and both parties were allowed time to file written comments in relation to the delegate's findings.  I have considered those comments.

    The framework of the Regulations

  3. Regulation 5.8 sets up a three stage procedure for the filing of evidence.  The opponent files its evidence in support, followed by the applicant's evidence in answer, and finally the opponent can respond with evidence in reply.  It is well established that evidence in reply is restricted to evidence rebutting the applicant's evidence in answer.  Evidence that merely bolsters the evidence in support or opens up new matters that should have been raised in evidence in support is not in reply (see Sonus Pharmaceuticals, Inc v Alliance Pharmaceutical Corp and Schering Aktiengesellschaft [2001] APO 13 (the Sonus decision)). 

  4. Where evidence is…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Merial Limited v Bayer Intellectual Property GmbH and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2015] APO 16
Decision Date

CaseChat Overview and Summary

This case involves a dispute between Merial Limited and Bayer Intellectual Property GmbH over a patent application (2007341647) titled "Agents for controlling parasites on animals." The patent application was filed by Bayer and is currently under opposition by Merial. The primary legal issues revolve around the admissibility of certain evidence in the context of opposition proceedings under the Patents Regulations, particularly focusing on whether specific evidence in reply was correctly classified and whether it should be considered under regulation 5.23. The dispute was heard and decided by Dr. S.D. Barker, a delegate of the Commissioner of Patents, on April 14, 2015.

The court was required to decide whether specific portions of evidence filed in reply were correctly classified as such, and whether certain documents not formally in evidence should be considered under regulation 5.23. Regulation 5.8 of the Patents Regulations establishes a three-stage procedure for filing evidence in opposition proceedings, with evidence in reply being restricted to rebutting the applicant's evidence in answer. The court also needed to interpret regulation 5.23, which allows the Commissioner to consult documents not formally in evidence but relevant to the opposition. The intent of this provision is to ensure that significant information is considered during the opposition to avoid delays post-opposition.

The court concluded that certain parts of the evidence filed by Dr. Jeffrey N. Clark and Mr. Joe R. Pippia were properly classified as evidence in reply, while paragraphs [50] – [52] of Dr. Clark's evidence and the references to document D18 in Dr. Leonore C. Witchey-Lakshmanan's declaration were not. The court determined that while the Commissioner has the discretion to consider documents under regulation 5.23, this should not be used as a substitute for the formal evidence process, and only highly significant information that is likely to change the outcome of the opposition should be considered. In this case, the court found that D18 was not sufficiently significant to warrant its consideration under regulation 5.23.

Background

Background to the litigation

This case concerns a patent application 2007341647 for "Agents for controlling parasites on animals" filed by Bayer Intellectual Property GmbH (Bayer). The patent application is under opposition by Merial Limited (Merial). The opposition involves various pieces of evidence submitted by both parties. Bayer filed evidence in reply, and subsequently, both parties challenged certain portions of this evidence. The key focus of the case is on whether specific parts of Bayer's evidence in reply are admissible and if certain new information brought to the Commissioner's attention should be considered under regulation 5.23.

The opposition to the patent application began with Merial filing evidence in support. Bayer responded with evidence in answer, followed by Bayer submitting evidence in reply. On 20 February 2015, Bayer informed the Commissioner that it believed certain parts of the evidence filed in reply were actually evidence in support filed out of time. A delegate of the Commissioner reviewed the matter and advised that most of the evidence in reply was admissible, except for certain parts related to a document designated as D18. Merial objected to this decision, leading to further written submissions. The case was ultimately decided by Dr. S.D. Barker, a delegate of the Commissioner of Patents, on 14 April 2015.

Decision

Reasons for decision

Issues
1. Are paragraphs [50] – [52] of the declaration of Dr Jeffrey N. Clark evidence in reply?
2. Are the references to D18 in the declaration of Dr Leonore C. Witchey-Lakshmanan evidence in reply?
3. Should D18 be relied upon under regulation 5.23 of the Patents Regulations?
4. Should paragraphs [50] – [52] of the evidence of Dr Clark be relied upon under regulation 5.23 of the Patents Regulations?

Held
1. Paragraphs [50] – [52] of the declaration of Dr Jeffrey N. Clark are not evidence in reply, and do not form part of the evidence in the opposition.
2. The references to D18 in the declaration of Dr Leonore C. Witchey-Lakshmanan are not evidence in reply, and do not form part of the evidence in the opposition.
3. D18 should not be relied upon under regulation 5.23 of the Patents Regulations.
4. Paragraphs [50] – [52] of the evidence of Dr Clark should not be relied upon under regulation 5.23 of the Patents Regulations.

Ratio Decidendi

Legal Principle Established

This case involved a determination of whether certain pieces of evidence were in reply and whether they could be relied upon under regulation 5.23 of the Patents Regulations. The court examined the evidence of Dr Clark, Mr Pippia, and Dr Witchey-Lakshmanan to determine if they were evidence in reply, which is evidence that rebuts the applicant's evidence in answer. The court concluded that the evidence of Dr Clark and Mr Pippia were in reply, except for paragraphs [50] – [52] of Dr Clark's declaration, and the references to D18 in Dr Witchey-Lakshmanan's declaration were not in reply.

The court then examined whether the Commissioner could rely on D18 and paragraphs [50] – [52] of Dr Clark's declaration under regulation 5.23 of the Patents Regulations, which allows the Commissioner to consult documents that are relevant to the opposition but have not been filed under the Chapter. The court held that a decision under regulation 5.23 must have regard to the nature of the information and whether the information is likely, if not certain, to change the outcome of the opposition in a significant way. The court found that D18 and paragraphs [50] – [52] of Dr Clark's declaration did not meet this threshold and therefore should not be relied upon under regulation 5.23.

The ratio decidendi of this case is that the Commissioner's discretion under regulation 5.23 of the Patents Regulations is not to be used as a substitute for the repealed further evidence provisions, and that the new information must be significantly better than what is already in evidence to be relied upon. The court distinguished the current regulation 5.23 from the former regulation 5.11, which allowed for the use of new information as a delaying tactic, and held that the Commissioner must form a view of the significance of the new information and invite comment on her proposed action before finalising her decision.